Skeletal Radiology

, Volume 43, Issue 9, pp 1319–1324 | Cite as

Diagnosis of osteosarcoma in a patient previously treated for Ewing sarcoma

  • Manabu Hoshi
  • Makoto Ieguchi
  • Kazumi Yamato
  • Sadao Tokimasa
  • Hiroaki Nakamura
Case Report


Primary malignant bone tumors, whether Ewing sarcoma or osteosarcoma, are a rare type of tumor. The sequential occurrence of two bone sarcomas, Ewing sarcoma and high-grade osteosarcoma, in the same patient at two different locations is an exceptionally rare phenomenon. We present the case of a 13-year-old girl who presented with a high-grade osteoblastic osteosarcoma of the distal femur, 7 years after treatment for Ewing sarcoma of the left pelvis. She did not receive radiation therapy. Following the recent developing multidisciplinary therapy, long-term follow-up for monitoring latent treatment-related adverse effects may be necessary for survivors of primary malignant bone tumors.


Osteosarcoma Ewing sarcoma Chemotherapy Latent adverse effect 



We thank Kenichi Wakasa for the pathological examinations and interpretations.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer. 2006;47:22–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Tsuchiya H, Tomita K, Mori Y, Asada N, Yamamoto N, Tsuchiya H, et al. Marginal excision for osteosarcoma with caffeine assisted chemotherapy. Clin Orthop Relat Res. 1999;358:27–35.PubMedCrossRefGoogle Scholar
  3. 3.
    Rosito P, Mancini AF, Rondelli R, Abate ME, Pession A, Bedei L, et al. Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer. 1999;86:421–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Rosen G, Caparros B, Nirenberg A, Marcove RC, Huvos AG, Kosloff C, et al. Ewing's sarcoma: ten-year experience with adjuvant chemotherapy. Cancer. 1981;47:2204–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Longhi A, Ferrari S, Tamburini A, Luksch R, Fagioli F, Bacci G, et al. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006). Cancer. 2012;118:5050–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Raymond AK, Ayala AG, Knuutila S. Conventional osteosarcoma. In: Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization classification of tumors: pathology and genetics; tumors of soft tissue and bone. Lyon: International Agency for Research on Cancer; 2002. p. 264–70.Google Scholar
  7. 7.
    Uni KK, Inwards CY. Osteosarcoma. In: Uni KK, Inwards CY, editors. Dahlin’s bone tumors. 6th ed. Philadelphia: Wolters Kluwer, Lippincott Williams & Wilkins; 2010. p. 122–57.Google Scholar
  8. 8.
    Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999;341:342–52.PubMedCrossRefGoogle Scholar
  9. 9.
    Evans RG, Nesbit ME, Gehan EA, Garnsey LA, Burgert Jr O, Vietti TJ, et al. Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the second intergroup study. J Clin Oncol. 1991;9:1173–80.PubMedGoogle Scholar
  10. 10.
    Bacci G, Forni C, Longhi A, Ferrari S, Donati D, De Paolis M, et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer. 2004;40:73–83.PubMedCrossRefGoogle Scholar
  11. 11.
    Fuchs B, Valenzuela RG, Petersen IA, Arndt CA, Sim FH. Ewing's sarcoma and the development of secondary malignancies. Clin Orthop Relat Res. 2003;415:82–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Navid F, Billups C, Liu T, Krasin MJ, Rodriguez-Galindo C. Second cancers in patients with the Ewing sarcoma family of tumours. Eur J Cancer. 2008;44:983–91.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Hayes FA, Thompson EI, Hustu HO, Kumar M, Coburn T, Webber B. The response of Ewing's sarcoma to sequential cyclophosphamide and adriamycin induction therapy. J Clin Oncol. 1983;1:45–51.PubMedGoogle Scholar
  14. 14.
    Meyer WH, Kun L, Marina N, Roberson P, Parham D, Rao B, et al. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone. J Clin Oncol. 1992;10:1737–42.PubMedGoogle Scholar
  15. 15.
    Marina NM, Pappo AS, Parham DM, Cain AM, Rao BN, Poquette CA, et al. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. J Clin Oncol. 1999;17:180–90.PubMedGoogle Scholar
  16. 16.
    Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol. 2009;27:2536–41.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Navid F, Santana VM, Billups CA, Merchant TE, Furman WL, Spunt SL, et al. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience. Cancer. 2006;106:1846–56.PubMedCrossRefGoogle Scholar
  18. 18.
    Sultan I, Rihani R, Hazin R, Rodriguez-Galindo C. Second malignancies in patients with Ewing sarcoma family of tumors: a population-based study. Acta Oncol. 2010;49:237–44.PubMedCrossRefGoogle Scholar
  19. 19.
    Ushigome S, Machinami R, Sorensen PH. Ewing sarcoma/primitive neuroectodermal tumor (PNET). In: Fletcher, CDM, Unni KK, Mertens F, editors. World Health Organization classification of tumors: pathology and genetics; tumors of soft tissue and bone. Lyon: International Agency for Research on Cancer 2002. p. 298–300.Google Scholar
  20. 20.
    Tsuchiya H, Tomita K, Yasutake H, Takagi Y, Katsuo S, Tokuumi Y, et al. Intraarterial cisplatin and caffeine with/without doxorubicin for musculoskeletal high-grade spindle-cell sarcoma. Oncol Rep. 1994;1:27–36.PubMedGoogle Scholar
  21. 21.
    Li FP, Fraumeni Jr JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358–62.PubMedGoogle Scholar
  22. 22.
    Kay RM, Eckardt JJ, Mirra JM. Osteosarcoma and Ewing's sarcoma in a retinoblastoma patient. Clin Orthop Relat Res. 1996;323:284–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Sharma V, Crawford AH, Evans J, Collins MH. Sequential Ewing's sarcoma and osteosarcoma. J Pediatr Orthop B. 2008;17:333–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Hosalkar HS, Atanda Jr A, Barroeta J, Torbert JT, Lackman RD. Case report: a rare case of Ewing’s sarcoma and osteosarcoma at different sites 10 years apart. Clin Orthop Relat Res. 2005;434:273–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Tucker MA, D'Angio GJ, Boice Jr JD, Strong LC, Li FP, Stovall M, et al. Newton W Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 1987;317:588–93.PubMedCrossRefGoogle Scholar

Copyright information

© ISS 2014

Authors and Affiliations

  • Manabu Hoshi
    • 1
  • Makoto Ieguchi
    • 1
  • Kazumi Yamato
    • 2
  • Sadao Tokimasa
    • 2
  • Hiroaki Nakamura
    • 1
  1. 1.Department of Orthopedic SurgeryOsaka City University Graduate School of MedicineOsakaJapan
  2. 2.Department of PediatricsOsaka City University Graduate School of MedicineOsakaJapan

Personalised recommendations